Welcome to this section dedicated to the financial community and to our shareholders. Here we make available our financial information, AGM reports as well as documents which have been presented to the financial community.

 

Neovacs is a public French biotechnology company developing therapeutic vaccines for the treatment for chronic autoimmune and inflammatory diseases. Listed on NYSE Alternext in Paris since 2010, it also enjoys long-term support from key shareholders.

Neovacs’ therapeutic vaccines are developed in severe diseases with unmet medical needs. The target market for Kinoids is estimated at over $27 billion (source: pharmaceutical company data), with potential to reach still broader markets.


Stock information

neovacs-logo alnev

ISIN code
Bloomberg
Reuters
Market
Sector
1st quotation
Number of shares

FR0004032746
ALNEV FP
ALNEV.PA
NYSE Alternext Paris
Pharmaceuticals & Biotechnology
April 21, 2010
23,006,310

 

Stock price

 


2015 Financial Calendar

  • Full-Year results 2014                  February 27, 2015
  • Shareholders’ AGM                      April 8,2015
  • Half-Year Results 2015                September 4, 2015